1267 related articles for article (PubMed ID: 19667304)
1. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS
Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304
[TBL] [Abstract][Full Text] [Related]
2. Survival with tiotropium compared to long-acting Beta-2-agonists in Chronic Obstructive Pulmonary Disease.
Gershon AS; Wang L; To T; Luo J; Upshur RE
COPD; 2008 Aug; 5(4):229-34. PubMed ID: 18671148
[TBL] [Abstract][Full Text] [Related]
3. Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.
Lee TA; Schumock GT; Bartle B; Pickard AS
Pharmacotherapy; 2009 Sep; 29(9):1039-53. PubMed ID: 19698009
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
Baker WL; Baker EL; Coleman CI
Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
[TBL] [Abstract][Full Text] [Related]
5. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.
Breekveldt-Postma NS; Koerselman J; Erkens JA; Lammers JW; Herings RM
Respir Med; 2007 Jul; 101(7):1398-405. PubMed ID: 17368011
[TBL] [Abstract][Full Text] [Related]
6. Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.
Cyr MC; Beauchesne MF; Lemière C; Aaron SD; Blais L
Ann Pharmacother; 2010 Apr; 44(4):613-22. PubMed ID: 20233915
[TBL] [Abstract][Full Text] [Related]
7. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Sobieraj DM; White CM; Coleman CI
Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
[TBL] [Abstract][Full Text] [Related]
8. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists.
Mapel DW; Hurley JS; Roblin D; Roberts M; Davis KJ; Schreiner R; Frost FJ
Respir Med; 2006 Apr; 100(4):595-609. PubMed ID: 16199151
[TBL] [Abstract][Full Text] [Related]
9. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
Suh DC; Lau H; La HO; Choi IS; Geba GP
Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
11. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking.
Kiri VA; Fabbri LM; Davis KJ; Soriano JB
Respir Med; 2009 Jan; 103(1):85-90. PubMed ID: 18793832
[TBL] [Abstract][Full Text] [Related]
12. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.
Tashkin DP
Expert Rev Respir Med; 2010 Jun; 4(3):279-89. PubMed ID: 20524910
[TBL] [Abstract][Full Text] [Related]
13. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
Mapel DW; Nelson LS; Lydick E; Soriano J; Yood MU; Davis KJ
COPD; 2007 Jun; 4(2):127-34. PubMed ID: 17530506
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization.
Gagnon YM; Levy AR; Spencer MD; Hurley JS; Frost FJ; Mapel DW; Briggs AH
Respir Med; 2005 Dec; 99(12):1534-45. PubMed ID: 16291076
[TBL] [Abstract][Full Text] [Related]
16. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs.
Drescher GS; Carnathan BJ; Imus S; Colice GL
Respir Care; 2008 Dec; 53(12):1678-84. PubMed ID: 19025702
[TBL] [Abstract][Full Text] [Related]
17. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
[TBL] [Abstract][Full Text] [Related]
18. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
Tashkin DP
Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
[TBL] [Abstract][Full Text] [Related]
19. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids.
Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
Respirology; 2006 Sep; 11(5):598-602. PubMed ID: 16916333
[TBL] [Abstract][Full Text] [Related]
20. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease.
Koumis T; Samuel S
Clin Ther; 2005 Apr; 27(4):377-92. PubMed ID: 15922812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
